Aridis Pharmaceuticals (ARDS) Stock Price
Aridis Pharmaceuticals Price
Aridis Pharmaceuticals (ARDS) Stock | ISIN US0403341045 | WKN A2N38H. The current Aridis Pharmaceuticals stock price is 0 USD (2026). Market capitalization is 3,755.46 USD. Aridis Pharmaceuticals operates in the Health sector.
Aridis Pharmaceuticals stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Aridis Pharmaceuticals over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Aridis Pharmaceuticals stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Aridis Pharmaceuticals's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Aridis Pharmaceuticals Price |
|---|
Aridis Pharmaceuticals Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Aridis Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement
| REVENUE (M USD) |
|---|
| REVENUE GROWTH (%) |
| GROSS MARGIN (%) |
| GROSS INCOME (M USD) |
| NET INCOME (M USD) |
| NET INCOME GROWTH (%) |
| SHARES (M) |
| DOCUMENTS |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Aridis Pharmaceuticals generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Aridis Pharmaceuticals retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Aridis Pharmaceuticals's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Aridis Pharmaceuticals has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Aridis Pharmaceuticals's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Aridis Pharmaceuticals stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Aridis Pharmaceuticals Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Aridis Pharmaceuticals business model & stock analysis
Aridis Pharmaceuticals SWOT Analysis
Strengths
Aridis Pharmaceuticals Inc has several key strengths that contribute to its success in the pharmaceutical industry. These strengths include:
- Strong Product Pipeline: Aridis Pharmaceuticals Inc has a robust pipeline of novel, potential life-saving anti-infective therapies, which provides a competitive edge in addressing unmet medical needs.
- Innovative Technologies: The company utilizes cutting-edge technologies such as fully human monoclonal antibodies and iron-acquisition strategies for developing its therapeutic candidates, positioning itself as a leader in the industry.
- Strategic Partnerships: Aridis Pharmaceuticals Inc has established strategic partnerships with leading pharmaceutical companies, enabling access to necessary resources, expertise, and potential market opportunities.
- Experienced Management Team: The company is led by a highly experienced management team with a successful track record in drug development and commercialization, ensuring effective decision-making and execution of strategies.
Despite its strengths, Aridis Pharmaceuticals Inc also faces certain weaknesses that could hinder its growth and competitive position. These weaknesses include:
- Dependency on Partnerships: The company's reliance on strategic partnerships for resources and market access may pose risks in terms of potential conflicts of interest or limitations in decision-making autonomy.
- Limited Product Portfolio: Aridis Pharmaceuticals Inc currently has a limited number of drugs in its portfolio, which may impact revenue generation and increase vulnerability to market-related fluctuations.
- Regulatory Challenges: The pharmaceutical industry is highly regulated, and any delays or difficulties in obtaining regulatory approvals could significantly impact the company's ability to bring its products to market in a timely manner.
- Financial Constraints: The company's financial resources may be limited, potentially hindering the ability to fully develop and commercialize its pipeline products or invest in new research and development initiatives.
Aridis Pharmaceuticals Inc can capitalize on several opportunities within the pharmaceutical sector to drive its growth and enhance its competitive position. These opportunities include:
- Increasing Demand for Anti-Infective Therapies: Given the rise in antibiotic resistance and the ongoing global health challenges, there is a growing demand for innovative anti-infective therapies, creating a significant market opportunity for the company.
- Emerging Markets: The company can expand its market presence into emerging economies where there is increasing healthcare spending and a rising prevalence of infectious diseases, offering potential for revenue growth.
- Strategic Collaborations: Aridis Pharmaceuticals Inc can explore additional collaborations with leading academic institutions, research organizations, or pharmaceutical companies to leverage their expertise, access new technologies, and strengthen its product pipeline.
- Government Support: The company may benefit from government initiatives, grants, or tax incentives aimed at the development of novel therapies or addressing public health concerns.
Aridis Pharmaceuticals Inc also faces certain threats that could potentially impact its business operations and market position. These threats include:
- Competitive Landscape: The pharmaceutical industry is highly competitive, with numerous well-established companies and emerging biotech firms. This competition poses a challenge in terms of market share acquisition and potential pricing pressures.
- Intellectual Property Protection: Protecting intellectual property rights is crucial in the pharmaceutical industry. Any infringement or challenges to the company's patents or proprietary technology could impact its ability to monetize its innovations or maintain a competitive edge.
- Clinical Trial Risks: The success of Aridis Pharmaceuticals Inc's pipeline products relies on the outcome of clinical trials. Unforeseen complications, ineffective results, or delays in trial completion can significantly impact the timeline and success of product commercialization.
- Regulatory and Compliance Changes: The pharmaceutical industry is subject to evolving regulations and compliance requirements. Changes in governmental policies or safety regulations may increase costs, cause delays, or impose additional burdens on the company's operations.
Weaknesses
Despite its strengths, Aridis Pharmaceuticals Inc also faces certain weaknesses that could hinder its growth and competitive position. These weaknesses include:
- Dependency on Partnerships: The company's reliance on strategic partnerships for resources and market access may pose risks in terms of potential conflicts of interest or limitations in decision-making autonomy.
- Limited Product Portfolio: Aridis Pharmaceuticals Inc currently has a limited number of drugs in its portfolio, which may impact revenue generation and increase vulnerability to market-related fluctuations.
- Regulatory Challenges: The pharmaceutical industry is highly regulated, and any delays or difficulties in obtaining regulatory approvals could significantly impact the company's ability to bring its products to market in a timely manner.
- Financial Constraints: The company's financial resources may be limited, potentially hindering the ability to fully develop and commercialize its pipeline products or invest in new research and development initiatives.
Aridis Pharmaceuticals Inc can capitalize on several opportunities within the pharmaceutical sector to drive its growth and enhance its competitive position. These opportunities include:
- Increasing Demand for Anti-Infective Therapies: Given the rise in antibiotic resistance and the ongoing global health challenges, there is a growing demand for innovative anti-infective therapies, creating a significant market opportunity for the company.
- Emerging Markets: The company can expand its market presence into emerging economies where there is increasing healthcare spending and a rising prevalence of infectious diseases, offering potential for revenue growth.
- Strategic Collaborations: Aridis Pharmaceuticals Inc can explore additional collaborations with leading academic institutions, research organizations, or pharmaceutical companies to leverage their expertise, access new technologies, and strengthen its product pipeline.
- Government Support: The company may benefit from government initiatives, grants, or tax incentives aimed at the development of novel therapies or addressing public health concerns.
Aridis Pharmaceuticals Inc also faces certain threats that could potentially impact its business operations and market position. These threats include:
- Competitive Landscape: The pharmaceutical industry is highly competitive, with numerous well-established companies and emerging biotech firms. This competition poses a challenge in terms of market share acquisition and potential pricing pressures.
- Intellectual Property Protection: Protecting intellectual property rights is crucial in the pharmaceutical industry. Any infringement or challenges to the company's patents or proprietary technology could impact its ability to monetize its innovations or maintain a competitive edge.
- Clinical Trial Risks: The success of Aridis Pharmaceuticals Inc's pipeline products relies on the outcome of clinical trials. Unforeseen complications, ineffective results, or delays in trial completion can significantly impact the timeline and success of product commercialization.
- Regulatory and Compliance Changes: The pharmaceutical industry is subject to evolving regulations and compliance requirements. Changes in governmental policies or safety regulations may increase costs, cause delays, or impose additional burdens on the company's operations.
Opportunities
Aridis Pharmaceuticals Inc can capitalize on several opportunities within the pharmaceutical sector to drive its growth and enhance its competitive position. These opportunities include:
- Increasing Demand for Anti-Infective Therapies: Given the rise in antibiotic resistance and the ongoing global health challenges, there is a growing demand for innovative anti-infective therapies, creating a significant market opportunity for the company.
- Emerging Markets: The company can expand its market presence into emerging economies where there is increasing healthcare spending and a rising prevalence of infectious diseases, offering potential for revenue growth.
- Strategic Collaborations: Aridis Pharmaceuticals Inc can explore additional collaborations with leading academic institutions, research organizations, or pharmaceutical companies to leverage their expertise, access new technologies, and strengthen its product pipeline.
- Government Support: The company may benefit from government initiatives, grants, or tax incentives aimed at the development of novel therapies or addressing public health concerns.
Aridis Pharmaceuticals Inc also faces certain threats that could potentially impact its business operations and market position. These threats include:
- Competitive Landscape: The pharmaceutical industry is highly competitive, with numerous well-established companies and emerging biotech firms. This competition poses a challenge in terms of market share acquisition and potential pricing pressures.
- Intellectual Property Protection: Protecting intellectual property rights is crucial in the pharmaceutical industry. Any infringement or challenges to the company's patents or proprietary technology could impact its ability to monetize its innovations or maintain a competitive edge.
- Clinical Trial Risks: The success of Aridis Pharmaceuticals Inc's pipeline products relies on the outcome of clinical trials. Unforeseen complications, ineffective results, or delays in trial completion can significantly impact the timeline and success of product commercialization.
- Regulatory and Compliance Changes: The pharmaceutical industry is subject to evolving regulations and compliance requirements. Changes in governmental policies or safety regulations may increase costs, cause delays, or impose additional burdens on the company's operations.
Threats
Aridis Pharmaceuticals Inc also faces certain threats that could potentially impact its business operations and market position. These threats include:
- Competitive Landscape: The pharmaceutical industry is highly competitive, with numerous well-established companies and emerging biotech firms. This competition poses a challenge in terms of market share acquisition and potential pricing pressures.
- Intellectual Property Protection: Protecting intellectual property rights is crucial in the pharmaceutical industry. Any infringement or challenges to the company's patents or proprietary technology could impact its ability to monetize its innovations or maintain a competitive edge.
- Clinical Trial Risks: The success of Aridis Pharmaceuticals Inc's pipeline products relies on the outcome of clinical trials. Unforeseen complications, ineffective results, or delays in trial completion can significantly impact the timeline and success of product commercialization.
- Regulatory and Compliance Changes: The pharmaceutical industry is subject to evolving regulations and compliance requirements. Changes in governmental policies or safety regulations may increase costs, cause delays, or impose additional burdens on the company's operations.
Aridis Pharmaceuticals Eulerpool Fair Value
Aridis Pharmaceuticals historical P/E ratio, EBIT multiple, and P/S ratio
Aridis Pharmaceuticals annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Aridis Pharmaceuticals shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Aridis Pharmaceuticals Earnings Estimates
Aridis Pharmaceuticals Earnings Estimates
| Date | EPS estimate | Revenue Estimate | Quarterly report |
|---|---|---|---|
| 5/20/2024 | -0.02USD | 306,000USD | 2023 Q4 |
| 3/29/2023 | 0.14USD | 20.88 MUSD | 2022 Q4 |
| 11/29/2022 | -0.17USD | 7.58 MUSD | 2022 Q3 |
| 8/16/2022 | -0.06USD | 10.62 MUSD | 2022 Q2 |
| 5/16/2022 | -0.52USD | 2.03 MUSD | 2022 Q1 |
| 4/1/2022 | -0.42USD | 1.93 MUSD | 2021 Q4 |
| 11/10/2021 | -0.52USD | 169,170USD | 2021 Q3 |
| 8/12/2021 | -0.64USD | 304,499USD | 2021 Q2 |
| 5/11/2021 | -0.63USD | 101,499USD | 2021 Q1 |
| 3/30/2021 | -0.61USD | 507,499USD | 2020 Q4 |
Aridis Pharmaceuticals shareholder structure
| % | Name |
|---|---|
27.52649% | |
27.14049% | |
7.73082% | |
7.54325% | |
0.02716% | |
0.01065% | |
% | |
% | |
% | |
% |
Aridis Pharmaceuticals Executives and Management Board
Dr. Vu Truong
(59)Chief Executive Officer, Co-Founder, Chief Scientific Officer, Director · since 2003
Dr. Hasan Jafri
(56)Chief Medical Officer
Dr. Eric Patzer
Co-Founder, Executive Chairman of the Board · since 2003
Mr. John Hamilton
(78)Independent Director
Dr. Susan Windham- Bannister
(73)Independent Director
Aridis Pharmaceuticals Supply Chain
Frequently asked questions about Aridis Pharmaceuticals
Aridis Pharmaceuticals Inc's business model revolves around the development and commercialization of innovative anti-infective therapies. The company focuses on utilizing its proprietary technology platforms to create monoclonal antibodies that can effectively target and neutralize infectious pathogens. By harnessing the power of the immune system, Aridis Pharmaceuticals aims to provide solutions for combating a wide range of infectious diseases, including bacterial, fungal, and viral infections. Through strategic partnerships and collaborations, the company aims to accelerate the development and commercialization of its product candidates, bringing much-needed therapeutic options to patients worldwide.
Aridis Pharmaceuticals stock
Aridis Pharmaceuticals Peer Group
Aridis Pharmaceuticals Ticker
Aridis Pharmaceuticals FIGI
All fundamentals and in-depth analysis of Aridis Pharmaceuticals
Our stock analysis for Aridis Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Aridis Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.